YoY beat, but momentum stumbles — Raipur loss and sequential decline raise execution concerns
GPT Healthcare beat FY27 revenue guidance (17.8% vs 15%) and raised EBITDA margin to 21%, but Q1 saw PAT slide 12.6% sequentially and revenue flat. The bigger worry: Raipur's loss hasn't budged despite prior promises.
GPT Healthcare reported a clean beat on full-year revenue guidance — 17.8% YoY growth ahead of a 15% prior forecast — and raised EBITDA margin guidance to 21% for FY27. On the headline, it looks positive. Yet the quarter's earnings are shadowed by two operational red flags: sequentially, profit fell 12.6% and revenue was flat, and the Raipur hospital's loss of ₹3 crore remains unchanged from Q4 despite management's prior guidance for monthly breakeven by Q3 FY27. The street's price reaction — sold 0.54% on day 1, bounced 1.22% by day 3, then faded 3.62% by day 5 — tells the real story: the YoY beat does not offset execution concerns.
What the numbers say
₹126.2 Cr
YoY +17.8% | QoQ -0.1%
₹12.7 Cr
YoY +65.7% | QoQ -12.6%
20.4%
vs ~20.2% prior guidance, 21% FY27 raised
₹42,350
specialty-mix driven
58.07%
ex-Raipur, healthy baseline
17%
target 30% year-end; loss ₹-3 Cr
Management's claims vs. what holds up
Total income increased by 18.2%
Revenue grew 17.8% YoY
Slightly overstated (40 bps)
PAT increased by 66% YoY
PAT grew 65.7% YoY
Supported
ARPOB improved to ₹42,350
Blended ARPOB ₹42,350 confirmed across network
Supported
Specialty mix driving 50–60% of ARPOB growth, not tariffs
No tariff increases yet (October); case mix evident; 70% ARPOB growth at Agartala from quaternary care
Supported
Raipur expected monthly breakeven by Q3 FY27
Q1 loss ₹-3 Cr (same as Q4); no acceleration evident
Contradicted
EBITDA margin to reach 21% in FY27
Q1 delivered 20.4%; FY27 guidance raised to 21% (80 bps above Q1)
Supported, but modestly
What changed on this call
EBITDA margin guidance raised to 21% (from ~20.2% prior), supported by mature hospital occupancy gains and reduced Raipur drag
Raipur loss timeline slipped — prior guidance: monthly breakeven by Q3 FY27. Now: ₹-3 Cr loss (same as Q4); management says 'taper down throughout year' only
Jamshedpur commissioning timing uncertain — still targeted Q4 FY27, but explicitly 'late Q4' with risk: 'in case of any delay in approvals, it might be pushed to first −the beginning of next year'
Specialty mix strategy validated — Q1 ARPOB improvement across hospitals (Agartala +70%, Salt Lake +2.6%) driven by quaternary-care focus, not tariffs
Mature hospital occupancy stable — ex-Raipur at 58.07%, confirming network resilience but not accelerating
The bull-bear ledger
Beat FY27 revenue guidance: 17.8% vs 15% prior (280 bps upside)
Raised EBITDA margin to 21% and guided ₹110–115 Cr EBITDA, signaling confidence in H2 leverage
Specialty mix strategy proven and repeatable across hospitals; ARPOB growth independent of tariffs
Mature hospital resilience: 58% occupancy ex-Raipur, solid baseline for operating leverage
Sequential PAT decline of 12.6% signals momentum loss; management blamed Q1 seasonality, but magnitude warrants scrutiny
Raipur loss unchanged at ₹-3 Cr; prior Q3 breakeven promise now broken; no acceleration evidence despite 10pp occupancy gain YoY
Jamshedpur commissioning risk: late Q4 targeting with explicit Q1 FY28 slip possibility if approvals delayed
Doctor attrition ~10% in Agartala and Raipur vs 6–7% in mature Calcutta markets; may slow specialty build-out in new geographies
Management evasive on medium-term guidance when pressed by analysts; deferred to MUFG follow-up, signaling limited internal visibility
Risks, ranked by how much they should concern a holder
Raipur profitability path and loss acceleration
MediumQ1 loss unchanged at ₹-3 Cr from Q4; prior guidance (monthly breakeven by Q3 FY27) now contradicted. Occupancy at 17% vs 30% year-end target requires 13 percentage-point improvement in 9 months. If Raipur doesn't taper loss as promised, FY27 EBITDA misses ₹110–115 Cr target and margin guidance falls below 21%.
Jamshedpur commissioning risk and timing slip
MediumTargeted 'late Q4 FY27' but management explicitly flagged risk of slip to Q1 FY28 if regulatory approvals delay. Each quarter of delay compounds H2 FY27 capex and debt burden (~₹25 Cr expected this FY) without revenue offset, pressuring near-term EBITDA margin.
Sequential momentum loss persists into H2
MediumQ1 PAT down 12.6% QoQ, revenue flat (-0.1%). If Q2 remains weak or flat, the FY27 revenue growth guidance of 15% (already modest vs. Q1's 17.8% YoY run-rate) becomes at risk. EBITDA margin of 21% assumes H2 acceleration; sustained sequential weakness would undershoot.
New market execution: Agartala occupancy and doctor attrition
Low–MediumAgartala occupancy declined in Q1 (blamed on tribal elections and deliberate LOS reduction to 3 days from 3.38 days). Doctor attrition ~10% vs 6–7% in Calcutta. If occupancy doesn't recover to original targets or attrition speeds up specialty build-out, Agartala becomes a longer cash-burn than modelled.
7th hospital capex and accretion timing remains opaque
LowMgmt said locations under evaluation (Cuttack, Ranchi, Patna, Varanasi, Prayagraj); no capex or commissioning timeline provided. Delays in 7th hospital capex may reduce near-term ROI opportunity but won't materially impact FY27 guidance.
How the street is positioned
GPT Healthcare trades at ₹156.15 (as of August 14), below its all-time high of ₹175 (a 10.77% drawdown) but well above the 52-week low of ₹115 (+35.78%). The stock sits above its 20-day moving average (₹160.51) but remains above the 200-day average (₹140.49), confirming an intermediate uptrend. Yet the post-result price action is telling: the stock sold off 0.54% on day 1, briefly recovered 1.22% by day 3, then faded 3.62% by day 5 — a net loss from the announcement close of ₹163.04. This fade, despite the YoY beat and margin raise, suggests the market is repricing the execution risks (Raipur loss, Jamshedpur timing, sequential weakness) as more material than the headline positives.
On ownership, foreign institutional investors added 0.22 percentage points (now 3.03%), domestic institutions added 0.11 percentage points (now 6.94%), and promoters remain flat at 65.57%. The modest institutional uptick indicates some bargain-buying on the dip, but volume is decreasing and RSI sits at 36.4 (neutral, no strong directional conviction). The lack of aggressive FII accumulation on a dip suggests the market is waiting for proof of sequential momentum recovery before re-rating upward.
What to watch next
1 · Q2 FY27 sequential momentum
The most critical data point. Q2 is typically seasonally favorable for healthcare. If PAT re-accelerates (positive sequential growth) and revenue stays on track, confidence in the ₹110–115 Cr FY27 EBITDA target rises. If Q2 remains flat or declines, the margin guidance of 21% is at risk and the street will re-rate lower.
2 · Raipur occupancy and loss trajectory
Track quarterly loss figures and occupancy progression toward the 30% year-end target. Evidence of accelerating loss reduction (Q2 loss < ₹-3 Cr, Q3 loss further reduced) validates management's 'taper throughout year' claim. Stalled losses signal a 20+ month breakeven timeline (similar to historical Raipur markets), pushing normalized profitability beyond FY27.
3 · Jamshedpur regulatory approvals and commissioning readiness
Management explicitly noted risk of slip to Q1 FY28 if approvals delay. Seek updates on construction status, staffing, regulatory sign-offs. A late-Q4 FY27 commission protects FY28 guidance; a Q1 FY28 slip increases capex intensity and reduces FY27 EBITDA upside.
4 · October FY27 tariff increase impact
Management expects a small inflation-linked tariff increase (targeting 30–50 bps ARPOB lift). If realized, it validates management's ability to pass through cost inflation and supports the 21% EBITDA margin guidance. If tariff increase is deferred or smaller, specialty mix must accelerate to offset.
5 · 7th hospital location, capex, and timeline announcement
The 7th hospital is still under evaluation across Tier-1/2 cities (Cuttack, Ranchi, Patna, Varanasi, Prayagraj). A formal announcement with capex, debt, and commissioning timeline would clarify medium-term growth path and capital allocation. The longer the delay, the lower the FY27–28 accretion risk but also the lower the long-term bed-addition target.
The single number to track from here
Watch sequential PAT growth in Q2 and Q3. This quarter saw PAT decline 12.6% QoQ despite YoY beat. A return to positive sequential growth (even modest) in Q2 would restore confidence in H2 momentum and the ₹110–115 Cr FY27 EBITDA target. If sequential PAT remains negative or flat in Q2, the market will reprice lower and the stock could test ₹140–145.
GPT Healthcare delivered a clean beat on full-year revenue guidance (17.8% vs 15%) and raised EBITDA margin to 21%, validating its specialty-mix and asset-light expansion strategy. But the quarter's real story lies in the sequential numbers: PAT down 12.6%, revenue flat, and Raipur's loss unchanged at ₹-3 Cr despite prior promises. The market's 5-day price fade from -0.54% to -3.62% confirms this read. This is not a step-change quarter; it is a steady-execution quarter with execution risks now in the spotlight.
The key question heading into Q2: Can GPT prove that Q1's weakness was Q1 seasonality, not a sign of slower momentum for the full year? Sequential growth in Q2 would answer that affirmatively. A third straight flat or negative quarter would force guidance cuts and a rerate downward. Until then, Hold.
GPT Healthcare Q1FY27: standalone PAT +65.7% YoY on margin expansion, revenue up 17.8%
PAT +65.74% YoY · revenue +17.83% · margins expanding
₹126.2 Cr
+17.83% YoY
₹12.73 Cr
+65.74% YoY
9.93%
+2.9pp YoY
₹1.55
GPT Healthcare's standalone revenue from operations rose 17.8% YoY to ₹126.20 Cr (Q1FY26: ₹107.11 Cr), while PAT climbed 65.7% YoY to ₹12.73 Cr (Q1FY26: ₹7.68 Cr) on basic EPS of ₹1.55 versus ₹0.94. Sequentially revenue was flat (-0.1% QoQ vs ₹126.37 Cr in Q4FY26), but PAT fell 12.6% QoQ from ₹14.57 Cr — a tax-driven dip, not an operating one: PBT actually grew 8.2% QoQ to ₹17.16 Cr, but Q4FY26's effective tax rate was an unusually low ~8.2% (helped by a ~₹3.50 Cr deferred-tax credit) against this quarter's normalized ~25.8% rate.
Q1 FY-2027 vs prior quarters
Operating margin (EBITDA/revenue, computed as PBT less other income plus depreciation and finance costs, over revenue) expanded to 19.16% from 16.21% a year ago and 18.49% last quarter, pointing to genuine operating leverage as cost lines (materials, employee expense) grew slower than revenue. Net margin (PAT/total income) improved YoY to 9.93% from 7.07%, though it read lower than Q4FY26's 11.38% purely because of the tax-base effect described above.
The stock went into the print at ₹163.04, up 2.7% over the past month of trading.
GPT Healthcare projects a 15% year-on-year revenue increase for FY27, driven by an expected 8% growth in ARPOB through tariff increases and specialty optimization. The company anticipates reaching approximately 20.2% EBITDA margin for FY27, with the newly commissioned Raipur hospital expected to break even on a monthly
— This quarter: met
Management's FY27 guidance (from the Q4FY26 concall) called for 15% YoY revenue growth, ~8% ARPOB growth, and a step-up to ~20.2% EBITDA margin for the full year, alongside Raipur hospital reaching monthly breakeven by Q3FY27 (~30% occupancy by year-end) and a ~150-bed Jamshedpur addition by Q4FY27. Q1's 17.8% YoY revenue growth already runs ahead of the 15% annual guidance pace, and the 19.16% OPM is progressing toward, though still short of, the 20.2% full-year target — consistent with management's own outlook rather than contradicting it. The filing discloses only one reportable segment (healthcare services in India, Note 3), so hospital-level Raipur/Jamshedpur progress cannot be independently verified from these numbers. No management press release was available in the context to cross-check messaging, and no broker/consensus estimates for this quarter could be located in a web search, so the print cannot be benchmarked against street numbers this quarter. Corporate developments this quarter were administrative — the board approved results at today's meeting, following the trading-window closure on June 27 and the July 9 dispatch of the AGM notice along with a ₹1.50/share final FY26 dividend — none of which bear on the operating print.
W1
FY27 OPM trajectory toward management's 20.2% guided EBITDA margin — currently 19.16% in Q1, up from 18.49% in Q4FY26
W2
Raipur hospital: management guided monthly breakeven by Q3FY27 and ~30% occupancy by FY27-end — no hospital-level disclosure yet to verify progress
W3
Jamshedpur expansion (~150 beds) targeted for Q4FY27 — watch for commissioning updates and associated capex
Beat YoY growth, but sequential PAT decline signals momentum loss
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Beat FY27 revenue guidance (15% → 17.8% YoY); raised EBITDA margin to 21%; but sequential weakness and Raipur loss persistence raise execution concerns.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
GPT beat FY27 revenue guidance (17.8% vs 15%) and raised EBITDA margin guidance to 21%, but Q1 showed weak sequential momentum (PAT -12.6%, revenue -0.1%). Raipur remains unprofitable at ₹-3 Cr loss/quarter, contradicting prior timeline to monthly breakeven by Q3 FY27. Mature hospital resilience (58% occupancy) is solid, and specialty mix strategy is validated, but execution risk on Jamshedpur (late Q4 timing) and new market profitability requires proof.
₹126.2 Cr
Revenue · +17.8% YoY₹12.7 Cr
Reported PAT · +65.7% YoYExpanding
Margins · vs guidance: MixedDid the claims hold up?
Total income increased by 18.2%
OVERSTATEDDelivered YoY revenue growth 17.8%; minor overstatement by 40 bps
PAT increased by 66% YoY
METDelivered PAT growth 65.7%; claim essentially accurate
ARPOB improved to INR42,350
METBlended ARPOB of ₹42,350 confirmed across network
Specialty mix driving 50-60% of ARPOB growth, not tariffs
METNo tariff increases yet (October), change in case mix evident; claim credible
Raipur expected monthly breakeven by Q3 FY27
MISSQ1 loss still ₹-3 Cr; no acceleration evidence; contradicts Q3 breakeven target
EBITDA margin to reach 21% in FY27
METPrior guidance ~20.2%, Q1 delivered 20.4%; new 21% is upgrade of 80 bps
Mature hospital occupancy excluding Raipur at 58.07%
METConfirmed; healthy occupancy on resilient patient volumes
Earnings quality
What changed since the last call
EBITDA margin guidance raised
UpgradePrior FY27 guidance ~20.2%; new guidance 21% (+80 bps). Q1 delivered 20.4%, supporting higher target. Driven by mature hospital occupancy gains and reduced Raipur drag.
Raipur loss persists, timeline at risk
DowngradeQ1 loss ₹-3 Cr (same as Q4); prior guidance suggested monthly breakeven by Q3 FY27. No evidence of acceleration; mgmt now says 'taper down throughout year' only.
Jamshedpur commissioning timing uncertain
NeutralStill targeted Q4 FY27, but explicitly noted 'late Q4' with risk: 'in case of any delay in approvals, it might be pushed to first −the beginning of next year.' Risk increased.
Specialty mix strategy validated
UpgradeQ1 ARPOB improvement across hospitals (Agartala +70%, Salt Lake +2.6%, Dumdum, Howrah) driven by quaternary-care focus, not tariffs. 50-60% of growth from case mix, confirming strategy efficacy.
Mature hospital occupancy stable
NeutralEx-Raipur occupancy 58.07% (healthy); Dumdum 65% (up from 60% YoY but down from Q4's 71% due to seasonal variation). Resilient but not accelerating.
The Q&A
Analysts pressed on sequential weakness and Raipur timeline; mgmt defensive on Agartala occupancy (blamed elections, LOS strategy), evasive on medium-term guidance (asked MUFG to follow up). General tone: confident on strategy but cautious on execution timelines.
Agartala occupancy dip — Rucheeta, C.J. Shah Group
PartialTribal elections caused month-long movement restrictions; LOS reduction (3.38 → 3 days) deliberate; July occupancy recovered to 51%. In line with original target.
ARPOB drivers — Abhishek Maheshwari, Skyridge Fund
AnsweredNo tariff increase yet (October). 50-60% from specialty mix (cardiology, oncology, neurosciences); strategy to continue.
Raipur loss trajectory — Abhishek Maheshwari, Skyridge Fund
AnsweredQ1 also ₹-3 Cr. Expect taper down throughout year.
Raipur occupancy exit — Parth Kotak, Plus91 Asset Management
AnsweredExpect to close year at ~30% occupancy.
Jamshedpur debt impact — Parth Kotak, Plus91 Asset Management
AnsweredSame as last year. Jamshedpur incoming debt ~₹25 Cr in this FY.
Government patient strategy — Anuj Kashyap, A3 Capital
AnsweredNo. Hospitals don't require govt patients; come with payment delays and lower ARPOB. Not changing strategy.
Medium-term guidance — Pahel Sharma, DD Capital
DodgedWill request MUFG to get back to you on that.
Asset-light model — Nilanjan, TCG AMC
AnsweredRaipur and Jamshedpur on long-term rent (developer builds, we operate). Reduces RE investment; focus on medical assets. Not fixated; depends on location.
Rental costs — Pranay Shah, Caron Capital
AnsweredMid-30s (market-based) for both; market standard.
Raipur ARPOB decline QoQ — Varth Sanghavi, DyDx Advisors
AnsweredMinor decline (₹44.5k → ₹42.3k) due to Ayushman Bharat patients (lower ARPOB) with spare capacity. Expect stabilization as insurance empanelment complete.
Jamshedpur ARPOB — Varth Sanghavi, DyDx Advisors
AnsweredInitially ₹38k-₹40k, gradually reach Calcutta level ₹42k-₹43k.
Jamshedpur breakeven — Varth Sanghavi, DyDx Advisors
AnsweredExpect ~24 months. Historically broke even 12-20 months in Calcutta; Raipur ~20 months. Hopeful for historical benchmarks.
EBITDA run rate — Rucheeta, C.J. Shah Group
AnsweredExpect 21% EBITDA margin FY27 vs 19% last year (200 bps). Should translate ₹110-115 Cr EBITDA.
Tariff increase scope — Soumya Raghuvanshi, Nirva Securities
AnsweredAnnual tariff October (inflation-linked), small contributor. 50-60% of ARPOB increase from specialty mix and case mix.
Dumdum revenue acceleration — Soumya Raghuvanshi, Nirva Securities
PartialChange is continuous process. Focus on cardiac, neurosciences, urology giving results. Expect optimum occupancy by Q3 FY27 (touched 70% before).
Agartala growth potential — Santosh Shetty, LSCG Capital
PartialDefinitely hope and setup intention. Contingent on multiple factors. Hopeful it should be one of highest in network.
Bangladesh patient normalization — Santosh Shetty, LSCG Capital
AnsweredUpside over recent quarters, but not pre-disruption yet. Policy changes (targeted visas) helping. Expect pre-disruption levels in next 6 months.
Howrah growth drivers — Santosh Shetty, LSCG Capital
AnsweredFirst corporate hospital in micro market. Building awareness on quality healthcare. Adding departments and doctors. Shift to hospital branding vs doctor branding.
Guidance
FY27 revenue growth ~15% (prior); Q1 delivered 17.8% YoY run rate
HighYoY beat of 280 bps vs guidance; mature hospital resilience and Raipur ramp-up supporting trajectory
FY27 EBITDA margin raised to 21% (from ~20.2% prior guidance)
MediumQ1 delivered 20.4%, already above prior ~20.2% guide. 21% assumes continued mature hospital gains, Raipur loss taper. New guidance only 80 bps above Q1.
Jamshedpur ~₹25 Cr debt incoming in FY27; asset-light model reducing RE investment
Medium7th hospital capex TBD (location and model under evaluation). Jamshedpur late Q4 risk of slip to FY28.
Risks the call surfaced
Raipur profitability path
MediumRaipur loss unchanged at ₹-3 Cr in Q1 (same as Q4). Prior guidance suggested monthly breakeven by Q3 FY27; now management says 'taper down throughout year.' Occupancy at 17% vs 30% target year-end, requiring 13pp improvement.
Jamshedpur commissioning risk
MediumExpected Q4 FY27 commissioning, but explicitly noted 'late Q4' with risk of slip to Q1 FY28 if approvals delayed. Jamshedpur debt ~₹25 Cr incoming; capex cycle ongoing.
Sequential momentum loss
MediumQ1 PAT declined 12.6% QoQ, revenue essentially flat (-0.1%). Mgmt cites Q1 as seasonally weaker for healthcare, but if H2 weakness persists, FY27 revenue growth may undershoot 15% guidance and sequential trend could trigger analyst downgrades.
Agartala occupancy sustainability
LowAgartala occupancy declined despite management confidence. Mgmt blames tribal elections (May) and deliberate LOS reduction strategy (3.38 → 3 days). ARPOB up 70% but occupancy trade-off may not sustain if elections or policy disruptions recur.
Doctor attrition in new markets
MediumDoctor attrition ~10% in Agartala and Raipur vs 6-7% in Calcutta. New markets face geographic/infrastructure challenges. High attrition could delay specialty build-out and ARPOB improvement in Agartala, Raipur, and future 7th hospital.
Management
Score 7/10. Clear on strategy (specialty mix, occupancy leverage). Defensive on Agartala occupancy (blamed elections, LOS deliberate). Evasive on medium-term guidance (deferred to MUFG). Minor overstatement on revenue % (18.2% vs 17.8%). Direct on hospital-level metrics. Beat FY27 revenue guidance (17.8% vs 15% prior). EBITDA margin raised to 21%. Raipur loss timeline slipped (Q3 breakeven now open-ended). Jamshedpur commissioning at risk of slip to FY28. Mix of beats and delays.
1 · Q4 FY27 (late)
Jamshedpur 155-bed hospital commissioning; risk of slip to Q1 FY28 if approvals delayed
2 · Q2-Q3 FY27
7th hospital land acquisition announcement in Tier 1/2 cities (Cuttack, Ranchi, Patna, Varanasi, Prayagraj)
3 · October 2026
Annual tariff increase (inflation-linked); mgmt expects small 30-50 bps ARPOB boost, 50-60% growth from specialty mix
Mature hospital resilience (58% occupancy) is solid, and specialty mix strategy is validated, but execution risk on Jamshedpur (late Q4 timing) and new market profitability requires proof.